Kimelman & Baird LLC Sells 34,267 Shares of Teleflex Incorporated (NYSE:TFX)

Kimelman & Baird LLC lessened its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 34.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 65,260 shares of the medical technology company's stock after selling 34,267 shares during the period. Kimelman & Baird LLC owned approximately 0.14% of Teleflex worth $11,615,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Avior Wealth Management LLC raised its position in Teleflex by 190.6% in the third quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company's stock worth $38,000 after acquiring an additional 101 shares during the period. True Wealth Design LLC increased its stake in shares of Teleflex by 16,600.0% during the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company's stock worth $41,000 after purchasing an additional 166 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Teleflex by 238.5% in the 4th quarter. IFP Advisors Inc now owns 308 shares of the medical technology company's stock worth $55,000 after purchasing an additional 217 shares during the period. Banque Cantonale Vaudoise lifted its stake in Teleflex by 184.8% in the third quarter. Banque Cantonale Vaudoise now owns 225 shares of the medical technology company's stock valued at $56,000 after purchasing an additional 146 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in Teleflex by 38.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 340 shares of the medical technology company's stock valued at $61,000 after purchasing an additional 94 shares during the period. 95.62% of the stock is owned by institutional investors.

Remove Ads

Teleflex Price Performance

NYSE TFX traded up $2.34 on Friday, hitting $141.77. The stock had a trading volume of 12,053,190 shares, compared to its average volume of 548,534. The firm has a 50-day moving average of $163.83 and a 200-day moving average of $195.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. Teleflex Incorporated has a 52-week low of $128.55 and a 52-week high of $249.91. The company has a market capitalization of $6.57 billion, a price-to-earnings ratio of 28.19, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.86 by $0.03. The company had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. Equities analysts expect that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Friday, March 7th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend was Friday, March 7th. Teleflex's dividend payout ratio is currently 95.77%.

Analysts Set New Price Targets

Several brokerages have issued reports on TFX. Needham & Company LLC restated a "hold" rating on shares of Teleflex in a research note on Wednesday, March 12th. StockNews.com cut Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, February 28th. Bank of America lowered shares of Teleflex from a "neutral" rating to an "underperform" rating and cut their target price for the stock from $235.00 to $140.00 in a research report on Tuesday, March 4th. Piper Sandler reissued a "neutral" rating and issued a $140.00 price target (down previously from $255.00) on shares of Teleflex in a research report on Friday, February 28th. Finally, Royal Bank of Canada cut shares of Teleflex from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $220.00 to $155.00 in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $182.63.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.